Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Synchronous Metastatic Esophageal Squamous Cell Carcinoma and Acute Myeloid Leukemia: A Case Report.

Created on 10 Aug 2026

Authors

Youssef Abbas, Mohammad Alaa Aldakak, Hamza Hdeoa, Bassel Ibrahim, Younes Souleiman

Published in

Cancer management and research. Volume 18. Pages 609006. Epub Aug 04, 2026.

Abstract

Synchronous presentation of solid and hematologic malignancies is uncommon, and coexistence of esophageal squamous cell carcinoma (ESCC) with acute myeloid leukemia (AML) at initial evaluation is exceptionally rare. Cytopenias may be misattributed to malnutrition, chronic disease, or the solid tumor itself.
A 57-year-old Syrian man who was a heavy smoker presented with progressive dysphagia, profound weight loss, weakness, and pallor. Endoscopy revealed a circumferential obstructing esophageal lesion. Computed tomography demonstrated a distal esophageal mass extending to the gastric cardia, para-aortic lymphadenopathy, and multiple hepatic lesions radiologically consistent with metastases. Histopathology showed invasive high-grade carcinoma with pseudo-signet ring morphology; mucin staining was negative, and immunohistochemistry supported high-grade ESCC (p40 positive; CK7 and CEA negative). Laboratory testing revealed severe pancytopenia (white blood cell count approximately 0.6 × 109/L, hemoglobin 6.9 g/dL, and platelets approximately 55 × 109/L) with markedly elevated lactate dehydrogenase. Bone marrow evaluation and flow cytometry identified approximately 46% myeloid blasts expressing CD117, CD34, CD33, CD13, myeloperoxidase, HLA-DR, and dim CD25, with aberrant CD7 expression in 31% of cells, establishing the diagnosis of AML. A feeding jejunostomy was placed for nutritional support, and the patient was referred for multidisciplinary management.
Severe or unexplained cytopenias in patients with esophageal malignancy warrant prompt hematologic evaluation, including bone marrow examination, to exclude a concomitant myeloid neoplasm and guide individualized treatment sequencing.
Synchronous metastatic ESCC and AML require early multidisciplinary assessment to avoid diagnostic delay and optimize supportive and disease-directed care.

PMID:
42572757
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement